Literature DB >> 7322212

Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages.

W Daniel, A Adamus, M Melzacka, J Szymura, J Vetulani.   

Abstract

Pharmacokinetics of imipramine (IMI) and its active metabolite, desipramine (DMI) was studied in rats after administration of a single dose of 10 mg/kg IMI, or after chronic administration of this dose once or twice a day for 14 days. The elimination curves of IMI and DMI from the blood and brain show that both the whole body and the brain behave as multi-compartment systems. Maximum concentrations of IMI and DMI in blood and brain appear at the same time, indicating rapid metabolism of IMI: the concentrations were significantly higher in the brain than in the blood. After the chronic treatment the maximum blood and cerebral levels of IMI and DMI were not much higher than after a single dose, but the elimination was slowed down. Brain concentration of IMI and DMI and brain IMI/DMI concentration ratio do not parallel those in the blood. After a prolonged treatment, once or twice a day, desipramine in the brain is present for the whole period between injections at concentrations sufficient to inhibit the noradrenaline uptake. If the drug is given twice a day, in addition to DMI also IMI is present for the whole time at concentration which may inhibit also serotonin uptake.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7322212     DOI: 10.1007/bf00503818

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain.

Authors:  J Vetulani; F Sulser
Journal:  Nature       Date:  1975-10-09       Impact factor: 49.962

2.  Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism.

Authors:  U Breyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs.

Authors:  D G Shand; J A Oates
Journal:  Biochem Pharmacol       Date:  1971-07       Impact factor: 5.858

4.  The total fate of a drug: kinetics of distribution, excretion, and formation of 14 metabolites in rats treated with imipramine.

Authors:  M H Bickel; H J Weder
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-06

5.  Studies on plasma level/effect relationships in imipramine therapy.

Authors:  J M Perel; R L Stiller; A H Glassman
Journal:  Commun Psychopharmacol       Date:  1978

6.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors:  W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

7.  [Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)].

Authors:  R Oliver-Marti n; E Buschsenschultz; P Pichot; J Boissier
Journal:  Psychopharmacologia       Date:  1975

8.  First-pass metabolism of imipramine in man.

Authors:  L F Gram; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

9.  Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.

Authors:  S B Ross; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

10.  SPECIES DIFFERENCES IN THE METABOLISM OF IMIPRAMINE AND DESMETHYLIMIPRAMINE (DMI).

Authors:  J V DINGELL; F SULSER; J R GILLETTE
Journal:  J Pharmacol Exp Ther       Date:  1964-01       Impact factor: 4.030

View more
  17 in total

1.  Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats.

Authors:  W Daniel; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats.

Authors:  W Daniel; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Role of calcium channels in effects of antidepressant drugs on responsiveness to pain.

Authors:  L Antkiewicz-Michaluk; I Romańska; J Michaluk; J Vetulani
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.

Authors:  W A Daniel; M Syrek; A Haduch; J Wójcikowski
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats.

Authors:  J V Cassella; M Davis
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat.

Authors:  C L DeVane; J W Simpkins; S A Stout
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Repeated imipramine enhances sensitivity of the brain dopaminergic system related to exploratory behavior.

Authors:  A Smiałowski
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

8.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

9.  Some effects of chronic antidepressant treatments on rat brain monoaminergic systems.

Authors:  M F Sugrue
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

10.  The effect of imipramine and desipramine on mixed function oxidase in rats.

Authors:  W Daniel; J Friebertshäuser; C Steffen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.